Biopharma Advances Demand Specialized Expertise

Jun 15, 2015
By BioPharm International Editors
Volume 2015 eBook, Issue 1

 

The approval of the first biosimilar in the United States, as well as continuing consolidation in the biopharma and contract development and manufacturing markets, are just two indicators of the ongoing evolution of biopharmaceutical development. Representatives of contract service providers shared observations, trends and projections with BioPharm International.

Read this article from BioPharm International’s 2015 Outsourcing Resources eBook.

View other articles in the 2015 Outsourcing Resources eBook.

 

 

 

 

 

native1_300x100
lorem ipsum